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Abstract
Background: Prior papers have been inconsistent regarding how much creatinine clearance (CrCl) overestimates
glomerular filtration rate (GFR). A recent cross-sectional study suggested that measurement error alone could
entirely account for the longstanding observation that CrCl/GFR ratio is larger when GFR is lower among patients
with chronic kidney disease (CKD); but there have been no validation of this in other cohorts.
Methods: To fill these gaps in knowledge regarding the relation between CrCl and GFR, we conducted cross-
sectional and longitudinal analysis of the Modification of Diet in Renal Disease study (MDRD) and African American
Study of Kidney Disease and Hypertension (AASK); and cross-sectional analysis of a clinical dataset from the Mayo
Clinic of four different patient populations (CKD patients, kidney transplant recipients, post kidney donation
subgroup and potential kidney donors). In the cross-sectional analyses (MDRD, AASK and Mayo Clinic cohort), we
examined the relation between the CrCl/iothalamate GFR (iGFR) ratio at different categories of iGFR or different
levels of CrCl. In the MDRD and AASK longitudinal analyses, we studied how the CrCl/iGFR ratio changed with
those who had improvement in iGFR (CrCl) over time versus those who had worsening of iGFR (CrCl) over time.
Results: Observed CrCl/iGFR ratios were generally on the lower end of the range reported in the literature for CKD
(median 1.24 in MDRD, 1.13 in AASK and 1.25 in Mayo Clinic cohort). Among CKD patients in whom CrCl and iGFR
were measured using different timed urine collections, CrCl/iGFR ratio were higher with lower iGFR categories but
lower with lower CrCl categories. However, among CKD patients in whom CrCl and iGFR were measured using the
same timed urine collections (which reduces dis-concordant measurement error), CrCl/iGFR ratio were higher with
both lower iGFR categories and lower CrCl categories.
Conclusions: These data refute the recent suggestion that measurement error alone could entirely account for the
longstanding observation that CrCl/GFR ratio increases as GFR decreases in CKD patients. They also highlight the
lack of certainty in our knowledge with regard to how much CrCl actually overestimates GFR.
Keywords: Chronic kidney disease (CKD), Glomerular filtration rate (GFR), Measurement error, Tubular secretion of
creatinine, Creatinine clearance (CrCl)
Background
Creatinine clearance (CrCl) has been used for decades as
a proxy measure for glomerular filtration rate (GFR),
and contemporary equations used to estimate GFR are
based on serum creatinine concentration [1, 2]. Besides
creatinine production and GFR, another factor which
can influence serum creatinine concentration is tubular
secretion (i.e. non-filtration clearance) of creatinine. But
there are surprising gaps in knowledge regarding the re-
lation between CrCl and GFR.
First, prior papers have been inconsistent regarding
the degree to which CrCl overestimates GFR, with
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estimates ranging from around 10% [3–7] to over 60%
[8, 9].
Second, we recently questioned whether the observed
larger ratio of CrCl to measured GFR among those with
lower GFR is actually due to proportionally greater tubu-
lar creatinine secretion with chronic kidney disease
(CKD) progression, as is commonly believed, or whether
this can be entirely accounted for by (random) measure-
ment error [3, 10]. But our prior study was limited since
it was based on only cross-sectional analysis of enrollees
from one CKD study (Chronic Renal Insufficiency Co-
hort [CRIC]), and the CrCl and measured GFR were not
obtained simultaneously [3].
To address these two issues, we sought to analyze
datasets where a larger number of patients had under-
gone measurement of both CrCl and GFR. The Modifi-
cation of Diet in Renal Disease study (MDRD) and
African American Study of Kidney Disease and Hyper-
tension (AASK) are ideal data sources since they are
both rigorously conducted cohorts and national in scope.
They have the additional advantage of containing re-
peated measured of both CrCl and GFR, thus allowing
us to perform longitudinal analyses and add a new di-
mension not present in our prior paper. We also con-
ducted cross-sectional analysis of 4 different Mayo
Clinic patient cohorts that underwent clinically-
indicated CrCl and GFR measurements that were per-
formed simultaneously (which should reduce dis-
concordant measurement error).
Methods
Study population
This study is based on information obtained from
MDRD study participants, AASK study participants and
a database of clinically obtained creatinine and iothala-
mate clearances performed at the Mayo Clinic, Roches-
ter, Minnesota. De-identified data from the MDRD and
AASK studies were obtained from the National Insti-
tutes of Diabetes and Digestive and Kidney Disease
(NIDDK) Data Repository after Institutional Review
Board (IRB) approval was obtained [11, 12]. The design
and baseline characteristic of the MDRD Study and
AASK Study have been previously described [13–18].
Briefly, in MDRD, 840 CKD patients aged 18–70 years
with measured GFR 13–55ml/min/1.73m2 were ran-
domized to determine the effects of usual vs. low vs.
very-low protein diet, and usual vs. low blood-pressure
targets. In AASK, 1094 African-Americans aged 18–70
years with GFR 20–65 ml/min/1.73m2 were randomized
to either strict versus usual BP control and different
anti-hypertensive agents. Both MDRD and AASK study
enrollees underwent repeated measures of urinary clear-
ance of iothalamate to quantify GFR and repeated 24-h
urine collections to quantify CrCl. To avoid the potential
for regression to the mean, we chose to conduct our
(cross-sectional and) longitudinal analyses in MDRD and
AASK starting at the 12-month visit after
randomization. After excluding enrollees who were
missing iothalamate GFR (iGFR) or CrCl, 797 MDRD
and 802 AASK participants remained with a measure-
ment at the 12-month study visit. Furthermore, 680
MDRD and 688 AASK participants had a subsequent
measurement of iGFR and CrCl at the 24-month study
visit and they constituted the study population for longi-
tudinal analysis.
The Mayo Clinic Renal Studies Unit database included
patients who had a urinary iothalamate clearance (iGFR)
with simultaneous timed urine creatinine from 2007 to
2012. The same urine collection (over a single timed
period) was used to quantify iGFR and CrCl. De-identified
data were obtained after appropriate IRB approval. For the
present analysis, we excluded patients < 18 years of age, on
dialysis, or with a history of urinary diversion. Also ex-
cluded were patients lacking a serum/plasma creatinine
from the same day as iGFR, and patients with an iGFR or
CrCl < 5ml/min/1.73m2 or > 300ml/min/1.73m2. Given
expected differences in level of kidney function and other
factors [19], we limited the current analysis to the four
most common indications for iGFR testing: CKD patients
(n = 1693), kidney transplant recipients (n = 1461), post
kidney donation subgroup (n = 206) and potential kidney
donors (n = 464) [19].
CrCl and GFR measurements
In the MDRD study, GFR was measured as the urinary
clearance of 125I-iothalamate (iGFR) after a subcutane-
ous injection of 35 microcuries without simultaneous
administration of epinephrine. GFR was calculated as
the ratio of time-weighted averages of urine excretion
rates of the iothalamate marker and the serum concen-
trations of the marker over three to four consecutive
collection periods [20]. The median intratest coefficient
of variation (CV) for iGFR was 9.4% [20]. Serum and
urine creatinine concentrations were measured by an al-
kaline picrate assay with Lloyd’s reagent and a kinetic al-
kaline picrate assay [21]. CrCl was calculated based on
UV/P from a single 24-h urine collection and like iGFR,
also standardized to body surface area.
In the AASK study, GFR was assessed by urinary clear-
ance of 125I-iothalamate (iGFR) after a subcutaneous in-
fection of 35 microcuries of 125I-iothalamate. GFR for
each 30-min period was calculated using the logarithmic
mean of the plasma 125I-iothalamate counts during the
period. The arithmetic mean of the four collection pe-
riods was used to calculate the GFR. In 3.5% of the in-
stances, GFR was calculated based on information from
three collection periods [22–24]. The median CV for
iGFR over the collection periods was 10.7% [22]. Serum
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and urine creatinine were measured using a kinetic alka-
line picrate assay (Jaffe method) at the AASK Central
Biochemistry Laboratory in the Department of Labora-
tory Medicine at Cleveland Clinic [23, 24]. CrCl was
computed from creatinine excretion in a 24-h urine col-
lection and a single measurement of serum creatinine
[23], and like iGFR, also standardized to body surface
area. In both MDRD and AASK cohorts, CrCl and iGFR
were quantified using different timed urine collections.
In the Mayo Clinic cohort, GFR was measured by renal
clearance of non-radiolabeled iothalamate [25]. The test
was performed under a standardized protocol in which
patients were fasted and underwent testing early in the
day to minimize the effects of diet and diurnal variation
on GFR. They were orally hydrated with 4–6 glasses of
water prior to subcutaneous injection of non-radiolabeled
iothalamate. Two hours later, renal clearance of iothala-
mate was measured over 45–60min. Plasma and urine
iothalamate concentrations were measured by liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
[26]. Serum or plasma creatinine values were obtained
using an isotope dilution mass spectrometry (IDMS)-
traceable Roche enzymatic method (Roche P or D Modu-
lar or Roche Cobas C501, Indianapolis, IN) using a blood
sample obtained within 24 h of the study. In contrast to
CRIC, MDRD and AASK, in the Mayo Clinic participants,
the same timed urine collection for each person was used
to determine GFR and CrCl.
Statistical analysis
In cross-sectional analyses (MDRD, AASK and Mayo
Clinic cohort), we examined the relation between CrCl/
iGFR ratio at different categories of iGFR or different
levels of CrCl as in our prior approach [3]. We studied
relative secretion of creatinine (CrCl/iGFR) because it is
widely reported in the literature.
In the MDRD and AASK longitudinal analyses, mim-
icking the analysis by Shemesh et al. [8], we first divided
the study population into those who had improvement
in iGFR over time versus those who had worsening of
iGFR over time. We then examined how the CrCl/iGFR
ratio changed in these two groups. We subsequently di-
vided the study population into those who had improve-
ment in measured CrCl over time versus those who had
worsening of measured CrCl over time to examine how
the CrCl/iGFR ratio changed in these two groups.
We used mean and standard deviation or median and
interquartile range as descriptive statistics to summarize
distributions of parameters of interest. All statistical ana-
lyses were carried out using IBM SPSS Statistics 20.0
(IBM Corporation, Armonk, NY). Analysis of the Mayo
data was independently confirmed using JMP software
Version 10.0 (SAS Institute, Cary, NC).
Results
Cross-sectional analysis in MDRD and AASK
Among 797 MDRD participants, the median CrCl was
34 (interquartile range [IQR], 22–49) ml/min/1.73m2
and median iGFR 28 (IQR, 18–39) ml/min/1.73m2. Me-
dian CrCl/iGFR ratio was 1.24 (IQR, 1.10–1.37). Of 674
MDRD participants with related data, the median time
lapse between 24-h urine collection and iGFR measure-
ment was 0 day (IQR 0–1 day).
Among 802 AASK participants, the median CrCl was
48 (IQR, 31–66) ml/min/1.73m2 and median iGFR 46
(IQR, 33–59) ml/min/1.73m2. Median CrCl/iGFR ratio
was 1.13 (IQR, 0.88–1.35).
We were able to replicate our prior CRIC cross-
sectional findings [3] in MDRD and AASK. Specific-
ally, the CrCl/iGFR ratio was progressively larger at
lower iGFR level when patients were classified by cat-
egories of iGFR in both MDRD and AASK (Fig. 1a)
(details in Additional files 1: Tables S1A and S2A).
However, when the same patients were classified by
categories of CrCl, the ratio of CrCl/iGFR was smaller
at lower CrCl level (Fig. 1b) (details in Additional file
1: Tables S1B and S2B). Similar results were seen
when tertiles of iGFR or CrCl were used for cutoff
(data not shown) or in continuous analysis (Add-
itional file 2: Figure S1 and S2).
Longitudinal analysis in MDRD and AASK
In longitudinal analyses, median time gap between re-
peat assessment of kidney function was 12.0 (IQR, 8.3–
12.3) months in 680 MDRD study participants. We
looked at subsets who had improvement in iGFR (CrCl)
over time versus those who had worsening of iGFR
(CrCl) over time because we were interested in figuring
out how the CrCl/iGFR ratio changed with iGFR (CrCl)
changed over time. The CrCl/iGFR ratio increased
among participants whose iGFR decreased over time,
but CrCl/iGFR ratio decreased among those whose iGFR
increased over time (Fig. 2); the opposite were observed
with changes in CrCl (Fig. 3). These parallel findings in
our cross-sectional analysis.
Similar results were observed in 688 AASK study par-
ticipants (median time gap between repeat assessment of
kidney function 12.2 (IQR, 11.7–17.1) months) (Add-
itional file 3: Figure S3 and S4).
Cross-sectional analysis in the Mayo Clinic subgroups:
between-group comparison
Among the four Mayo Clinic subgroups, the potential
kidney donors had the highest median iGFR (97 ml/min/
1.73m2), followed by the post kidney donation subgroup
(64 ml/min/1.73m2), the kidney transplant recipients (48
ml/min/1.73m2) and the CKD patients (41 ml/min/
1.73m2) (Table 1).
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The median CrCl/iGFR ratio was lowest in the poten-
tial kidney donors (1.05), followed by the post kidney
donation subgroup (1.09), the kidney transplant recipi-
ents (1.25) and the CKD patients (1.25) (Table 1). Thus,
in this between group comparison, lower kidney func-
tion—quantified both by iGFR and CrCl--was associated
with a higher CrCl/iGFR ratio.
Cross-sectional analysis in the Mayo Clinic subgroups:
within group comparison
Within each of the 4 Mayo Clinic cohort subgroups,
the CrCl/iGFR ratio in general were progressively
larger with lower iGFR levels (Table 2) (details in
Additional file 1: Table S3_1A, S3_2A, S3_3A and
S3_4A).
Fig. 1 Distribution of iGFR, CrCl, as well as CrCl/iGFR ratio stratified by categories of iGFR (a) and by categories of CrCl (b) in 802 AASK, 797 MDRD
and 1693 Mayo CKD participants (box plots show median, interquartile range and outliers; whiskers represent the highest and lowest values that
are not outliers more than 1.5 box lengths from one hinge of the box). The data in the figure represents the corresponding median
CrCl/iGFR ratios
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When the participants were classified by categories of
CrCl, the ratio of CrCl/iGFR were smaller with lower
CrCl level in the Mayo Clinic potential kidney donors
and post kidney donation subgroup (Table 2) (details in
Additional file 1: Table S3_3B and S3_4B).
In the transplant recipients, there was not a simple step-
wise relation between CrCl/iGFR ratio and categories of
CrCl, but below CrCl of 75ml/min/1.73m2 the ratio of
CrCl/iGFR were progressively larger with lower CrCl level
(Table 2) (details in Additional file 1: Table S3_2B).
However, among the Mayo Clinic CKD patients--in
contrast to what was observed in the CKD populations
of CRIC, MDRD and AASK--the ratio of CrCl/iGFR
were progressively larger with lower CrCl level (Table 2,
Fig. 1b) (details in Additional file 1: Table S3_1B).
Discussion
Although it has been known for many years that creatin-
ine is cleared via both filtration and secretion, basic gaps
remain in our knowledge regarding the physiology and
pathophysiology of tubular secretion of creatinine in
various states of health and disease. For example, exactly
what fraction of creatinine is cleared via secretion vs. fil-
tration? Is it possible that measurement error alone
Fig. 2 Change in mean (±standard deviation [SD]) iGFR and mean (±SD) CrCl/iGFR ratio longitudinally among MDRD study participants divided
into those with decreasing iGFR (n = 508) or increasing iGFR (n = 172)
Fig. 3 Change in mean (±SD) CrCl and mean (±SD) CrCl/iGFR ratio longitudinally among MDRD study participants divided into those with
decreasing CrCl (n = 489) or increasing CrCl (n = 191)
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could entirely account for the longstanding observation
that CrCl/GFR ratio is larger at lower GFR among pa-
tients with CKD? These questions are pertinent in the
context of renewed recent interest in renal tubular func-
tion [27–29]. Better understanding of tubular secretion
as an independent marker of kidney function may pro-
vide insight into kidney disease pathophysiology and im-
prove prediction of adverse outcomes [27]. Others have
emphasized that many drugs are cleared by tubular se-
cretion, and drug-dose modification in CKD should not
assume that renal excretory processes always decline in
parallel with GFR as CKD progresses [30].
In this study we showed the following. First, we are
able to replicate the results of our original CRIC cross-
sectional results in MDRD and AASK [3]. Replicating
our initial findings in two other large research cohorts
underscores the idea that certain studies in the literature
may have been biased by measurement error, which has
been under-appreciated in the past. (In fact, measure-
ment error has not been mentioned at all in the prior lit-
erature as far as we can tell.)
Second (and closely related conceptually), we demon-
strate that measurement error likely played an under-
appreciated role also in prior literature that describes lon-
gitudinal changes in the CrCl/GFR ratio. For example, in
the much cited study by Shemesh et al. [8], the authors
concluded from their longitudinal analysis that “The op-
posite changes in fractional creatinine secretion and GFR
as glomerular disease deteriorates or improves serve to
blunt the magnitude of change when creatinine is used to
monitor progression of the glomerular injury [8].” Not
considered by the authors is the fact that measurement
error alone may explain much of this observation.
Third, since inaccurate collection of urine specimens is
the biggest source of measurement error for directly mea-
sured GFR and CrCl by urinary clearance, when both CrCl
and GFR were measured using the same timed urine col-
lections, the role of measurement error should be consid-
erably reduced. In this context, the findings in the Mayo
Clinic cohort CKD patients (and kidney transplant recipi-
ents with CrCl < 75ml/min/1.73m2) are of particular
interest. In these cohorts that used the same urine collec-
tion to quantify iGFR and CrCl we no longer observed a
decreasing CrCl/iGFR ratio at progressively lower CrCl.
Instead, in these patients the CrCl/iGFR ratio goes up in
cross-sectional analysis with progressively lower CrCl (and
progressively lower iGFR). This—and the between-group
comparisons shown in Table 1---supports the textbook
teaching that there is indeed proportionally greater tubu-
lar creatinine secretion with worsening kidney function
(since those with lower CrCl have worse kidney function).
These data demonstrate that measurement error alone
could not entirely account for the longstanding observa-
tion that CrCl/GFR ratio increases as GFR decreases in
patients with CKD.
Fourth, we note that there is considerable variation in
the average CrCl/iGFR ratio across studies. In CRIC study,
the median ratio was 1.09 [3]. In MDRD study it was 1.24
and in AASK study it was 1.13. One problem is that these
and other older studies [3–9] were done prior to the era
of standardization of the IDMS-traceable reference cali-
brator. Another problem is that different studies used dif-
ferent methods to measure GFR and these are known to
be inconsistent with each other [31–33], thus rendering
definitive conclusions difficult. Even within our study,
serum creatinine was measured using the enzymatic
method at the Mayo Clinic but not in MDRD or AASK.
The alkaline picrate method for the measurement of cre-
atinine can be influenced by non-creatinine chromogens
(such as acetoacetate and some antibiotics), especially on
older platforms [34]. The so-called ‘Jaffe’ method has no
standard recipe and much methodological variation has
occurred over time [35]. Interestingly in the Mayo Clinic
data (Table 2), the CrCl/iGFR ratio appears to differ by
type of clinical presentation. For example, for the category
of iGFR 60–74ml/min/1.73m2, median CrCl/iGFR ratio
was 1.18 in CKD patients but 1.04 in the post kidney do-
nation subgroup. So perhaps it appears that despite de-
cades of research and seemingly definitive statements in
textbooks and review articles, we in fact do not know with
certitude the degree by which CrCl overestimates GFR.
Strengths of our study include validation of our
prior findings (in CRIC) [3] from two other large
CKD research studies (MDRD and AASK). We ex-
tended our cross-sectional analysis to longitudinal
analyses to bring attention to the fact that measure-
ment error could also have contributed to prior re-
port of temporal changes in CrCl/GFR over time
within a person [8]. Finally, the Mayo Clinic data,
based on using the same timed urine collection to
measure CrCl and GFR, shed new light on the limited
role of measurement error.
Table 1 The distribution of iGFR, CrCl and CrCl/iGFR ratio in the 4 different subgroups of the Mayo Clinic cohort
Groups iGFR (ml/min/1.73m2) Median (IQR) CrCl (ml/min/1.73m2) Median (IQR) CrCl/iGFR ratio Median (IQR)
Potential kidney donors (n = 464) 97 (85, 111) 102 (87, 116) 1.05 (0.96, 1.14)
Post kidney donation subgroup (n = 206) 64 (56, 73) 68 (61, 78) 1.09 (1.01, 1.19)
Kidney transplant recipients (n = 1461) 48 (34, 60) 58 (45, 72) 1.25 (1.09, 1.42)
CKD patients (n = 1693) 41 (25, 65) 52 (35, 77) 1.25 (1.11, 1.45)
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We also recognize several limitations. First, we did not
measure iGFR and CrCl using the same blood samples
in the Mayo Clinic patients which would have even fur-
ther reduced measurement error. But previous Mayo
Clinic studies have confirmed that a routine fasting
morning serum creatinine drawn within 24-h of the
study and a plasma creatinine obtained during the iotha-
lamate study do not significantly differ (data not shown).
Second, we did not have information on the concomi-
tant use of drugs, such as trimethoprim or cimetidine,
which could have affected tubular secretion of
creatinine. Third, we did not perform interventional
studies with agents such as cimetidine to examine the ef-
fect of blocking tubular secretion of Cr [36–39]. How-
ever, these experiments are not straightforward since
cimetidine is cleared by the kidneys, so in patients with
more advanced CKD, less cimetidine is filtered and more
cimetidine becomes available in the proximal tubular
pericapillary circulation. Thus, more cimetidine enters
the proximal tubular cells to compete with creatinine for
the brush border (luminal) secretory transporter [39]. It
is also not clear how complete inhibition can be
Table 2 CrCl/iGFR ratio by categories of iGFR or CrCl (Mayo Clinic cohort subgroups)
CKD
patients
(n = 1693)
iGFR category (ml/min/1.73m2)
≥75 (n = 316) 60–74 (n = 168) 45–59 (n = 275) 30–44 (n = 355) < 30 (n = 579) P
CrCl/
iGFR
ratio
1.08 (0.97, 1.21) 1.18 (1.06, 1.32) 1.21 (1.09, 1.32) 1.28 (1.14, 1.43) 1.43 (1.26, 1.68) < 0.001
CrCl category (ml/min/1.73m2)
≥75 (n = 453) 60–74 (n = 231) 45–59 (n = 321) 30–44 (n = 377) < 30 (n = 311)
CrCl/
iGFR
ratio
1.18 (1.05, 1.36) 1.22 (1.06, 1.35) 1.23 (1.11, 1.40) 1.33 (1.16, 1.54) 1.34 (1.17, 1.55) 0.005
Kidney
transplant
recipients
(n = 1461)
iGFR category (ml/min/1.73m2)
≥75 (n = 132) 60–74 (n = 239) 45–59 (n = 430) 30–44 (n = 410) < 30 (n = 250)
CrCl/
iGFR
ratio
1.04 (0.91, 1.19) 1.14 (1.02, 1.29) 1.17 (1.06, 1.33) 1.31 (1.19, 1.46) 1.51 (1.35, 1.77) < 0.001
CrCl category (ml/min/1.73m2)
≥75 (n = 310) 60–74 (n = 341) 45–59 (n = 447) 30–44 (n = 263) < 30 (n = 100)
CrCl/
iGFR
ratio
1.29 (1.12, 1.44) 1.19 (1.05, 1.36) 1.22 (1.06, 1.39) 1.27 (1.10, 1.50) 1.39 (1.18, 1.63) < 0.001
Post
kidney
donation
subgroup
(n = 206)
iGFR category (ml/min/1.73m2)
≥75 (n = 42) 60–74 (n = 91) < 60 (n = 73)
CrCl/
iGFR
ratio
1.06 (0.99, 1.13) 1.04 (0.97, 1.15) 1.14 (1.02, 1.31) < 0.001
CrCl category (ml/min/1.73m2)
≥75 (n = 75) 60–74 (n = 85) < 60 (n = 46)
CrCl/
iGFR
ratio
1.15 (1.06, 1.22) 1.06 (1.00, 1.17) 1.02 (0.91, 1.12) < 0.001
Potential
kidney
donors
(n = 464)
iGFR category (ml/min/1.73m2)
≥110 (n = 123) 90–109 (n = 175) < 90 (n = 166)
CrCl/
iGFR
ratio
0.98 (0.89, 1.07) 1.06 (0.97, 1.13) 1.09 (1.00, 1.19) < 0.001
CrCl category (ml/min/1.73m2)
≥110 (n = 159) 90–109 (n = 170) < 90 (n = 135)
CrCl/
iGFR
ratio
1.10 (1.01, 1.20) 1.04 (0.96, 1.13) 0.99 (0.87, 1.08) < 0.001
All the data are expressed as median (IQR)
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established. Interestingly, one older study which
attempted to do that reported that “amount of overesti-
mation of true GFR by creatinine clearance was not as-
sociated with extent of renal functional impairment
[37].” However, other studies suggested that the tubular
secretion of cimetidine increases inversely with GFR [36,
38, 39].
Conclusions
To close, our prior study highlighted measurement error
as alternative interpretation of the literature which has
hitherto not been considered [3]. The current study dem-
onstrates that measurement error alone could not entirely
account for the longstanding observation that CrCl/GFR
ratio increases as GFR decreases in patients with CKD.
Our data also draw attention to gaps in knowledge with
regard to how much CrCl actually overestimates GFR,
despite decades of literature on this topic.
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1186/s12882-020-01736-6.
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categories based on iGFR and CrCl (Mayo data, post kidney donation
subgroup). Table S3_4. CrCl/iGFR classified by categories based on iGFR
and CrCl (Mayo data, potential kidney donors).
Additional file 2 Fig. S1. (A) Relationship between CrCl/iGFR ratio and
iGFR, (B) Relationship between CrCl/iGFR ratio and CrCl (The line shown
through the scatterplot is from LOESS) (MDRD data, n = 797). Fig. S2. (A)
Relationship between CrCl/iGFR ratio and iGFR, (B) Relationship between
CrCl/iGFR ratio and CrCl (The line shown through the scatterplot is from
LOESS) (AASK data, n = 802).
Additional file 3 Fig. S3. Change in mean (±SD) iGFR and mean (±SD)
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(±SD) CrCl and mean (±SD) CrCl/iGFR ratio longitudinally among AASK
study participants divided into those with decreasing CrCl or increasing
CrCl.
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